Autres langues CSPC Pharmaceutical Group Limited

Actions

1093

HK1093012172

Produits pharmaceutiques

Marché Fermé - Hong Kong S.E. 10:08:14 25/09/2026			Varia. 5j.	Varia. 1 janv.
9,330 ^HKD	-0,11 %		+5,42 %	+10,68 %

24/09	CSPC Pharmaceutical Group Limited lance en Chine un essai clinique de phase III du docétaxel injectable lié à l’albumine (HB1801) dans le traitement du cancer du sein avancé	CI
24/09	CSPC Pharmaceutical Group Limited annonce des résultats préliminaires positifs pour l’essai clinique de phase III du Becotatug associé à l’osimertinib	CI

Autres langues

24/09	CSPC Pharmaceutical Group Limited Initiates Phase III Clinical Trial Of Docetaxel For Injection (Albumin-Bound) For Treatment Of Advanced Breast Cancer In China
24/09	CSPC Pharmaceutical Group Limited Announces Phase III Clinical Trial Of Becotatug In Combination With Osimertinib Achieves Positive Topline Results
24/09	CSPC Pharma's Phase III Trial of Lung Cancer Drug Combo Achieves Positive Topline Results
24/09	CSPC Pharm Begins Phase III Breast Cancer Drug Trial
21/09	Pharma sector doubles down on AI to slash costs, timelines
21/09	US Considers Rules Allowing American Investment in Chinese Drugs
16/09	CSPC Pharmaceutical Group Limited Initiates Phase II Clinical Trial Of SYH2069 Injection For Treatment Of Type 2 Diabetes Mellitus In Adult Patients At First Centre In China
16/09	Pharma sector doubles down on AI to slash costs, timelines
16/09	CSPC Pharma Begins Diabetes Drug Trial in China
15/09	CSPC Pharmaceutical Gets Breakthrough Therapy Designation for Lung Cancer Drug
15/09	CSPC Pharmaceutical says SYS6010 granted breakthrough therapy designation by NMPA
15/09	CSPC Pharmaceutical Group Limited Receives Breakthrough Therapy Designation For SYS6010 By NMPA In China For Treatment Of Actionable Genomic Alteration-Negative Non-Squamous Non-Small Cell Lung Cancer
14/09	CSPC Pharmaceutical Group Limited Presents Phase I/II Clinical Trial Data Of SYS6010 In Combination With Enlonstobart For Treatment Of Advanced NSCLC At 2026 World Conference On Lung Cancer
09/09	CSPC Pharma's SYH9087 Injection Gets China Nod for Parkinson's Disease Trial
09/09	CSPC Pharma Gets Clinical Trial Nod in China for Solid Tumors Drug
09/09	CSPC Pharmaceutical Group Limited Announces Dopamine Receptor Agonist Rotigotine Long-Acting Injection (SYH9087 Injection)
09/09	CSPC Pharmaceutical Group Limited Obtains Clinical Trial Approval In China For Goserelin Sustained-Release Injection (SYH9102 Injection)
08/09	CSPC Pharmaceutical Group Limited SYH2083 Eye Drops Obtain Clinical Trial Approval In China
08/09	CSPC Pharmaceutical Gets China Approval for Eye Drug Clinical Trials
07/09	CSPC Pharmaceutical Group Limited Initiates Phase II Clinical Trial of SYH2085 Tablets for Treatment of Uncomplicated Influenza in Adults in China
07/09	CSPC Pharma Begins Phase II Study of Influenza Drug in China
01/09	CSPC Pharma's Cancer Drug Gets Breakthrough Therapy Designation for New Indication in China
01/09	CSPC Pharma's SYS6010 Gets Breakthrough Therapy Designation for New Indication in China
01/09	CSPC Pharma Initiates Depression Drug Candidate Trial in China
01/09	CSPC Pharmaceutical Group Limited Initiates Phase I Clinical Trial Of SYH2056 Tablets For The Treatment Of Depression In China